CRIS Current Research Information System

DE GIOVANNI, CARLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.867
AS - Asia 3.299
EU - Europa 2.835
AF - Africa 281
SA - Sud America 180
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 6
Totale 11.477
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.787
VN - Vietnam 1.119
SG - Singapore 822
CN - Cina 760
GB - Regno Unito 715
IT - Italia 515
DE - Germania 345
SE - Svezia 257
HK - Hong Kong 224
FR - Francia 174
RU - Federazione Russa 160
UA - Ucraina 157
IN - India 146
BR - Brasile 127
CH - Svizzera 127
CI - Costa d'Avorio 106
IE - Irlanda 98
ZA - Sudafrica 73
JP - Giappone 60
NL - Olanda 60
TG - Togo 56
CA - Canada 54
EE - Estonia 43
BG - Bulgaria 33
FI - Finlandia 33
BE - Belgio 31
AR - Argentina 20
KR - Corea 20
SC - Seychelles 20
PH - Filippine 17
BD - Bangladesh 16
ID - Indonesia 16
RO - Romania 15
TH - Thailandia 15
PL - Polonia 14
TR - Turchia 14
MX - Messico 13
EC - Ecuador 12
LT - Lituania 12
NG - Nigeria 11
TW - Taiwan 11
ES - Italia 10
JO - Giordania 10
CL - Cile 9
CO - Colombia 8
HR - Croazia 7
IQ - Iraq 7
AT - Austria 6
AU - Australia 6
SA - Arabia Saudita 6
UZ - Uzbekistan 6
EG - Egitto 5
GR - Grecia 5
IR - Iran 5
PK - Pakistan 5
AE - Emirati Arabi Uniti 4
DK - Danimarca 4
EU - Europa 4
CR - Costa Rica 3
CZ - Repubblica Ceca 3
PS - Palestinian Territory 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AZ - Azerbaigian 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
JM - Giamaica 2
KH - Cambogia 2
MD - Moldavia 2
MY - Malesia 2
NZ - Nuova Zelanda 2
PA - Panama 2
PE - Perù 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
AL - Albania 1
AM - Armenia 1
AO - Angola 1
BO - Bolivia 1
BY - Bielorussia 1
DM - Dominica 1
DZ - Algeria 1
GP - Guadalupe 1
IL - Israele 1
KE - Kenya 1
KG - Kirghizistan 1
LI - Liechtenstein 1
LU - Lussemburgo 1
LV - Lettonia 1
MA - Marocco 1
NP - Nepal 1
NR - Nauru 1
OM - Oman 1
PT - Portogallo 1
PY - Paraguay 1
RS - Serbia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TJ - Tagikistan 1
YE - Yemen 1
Totale 11.476
Salva come PNG Salva come JPEG
Città #
Southend 580
Singapore 546
Fairfield 523
Ashburn 507
Chandler 484
Houston 270
Woodbridge 242
Ho Chi Minh City 229
Wilmington 229
Hong Kong 212
Ann Arbor 208
Seattle 202
Hanoi 199
San Jose 188
Dong Ket 161
Cambridge 155
Princeton 149
Santa Clara 145
Bologna 135
Abidjan 106
Jacksonville 106
Bern 101
Dublin 97
Beijing 96
Boardman 93
Dallas 65
Hefei 64
Lauterbourg 59
Nanjing 59
Westminster 59
Council Bluffs 56
Lomé 56
Padova 54
Tokyo 53
Los Angeles 50
Berlin 39
Bremen 36
New York 36
Haiphong 35
Jinan 34
Buffalo 33
Sofia 32
Brussels 31
Da Nang 31
San Diego 31
Milan 29
Redwood City 29
Guangzhou 28
Helsinki 28
Saint Petersburg 28
Shenyang 26
Mülheim 23
Phoenix 23
Nanchang 22
São Paulo 22
Tianjin 22
Hebei 21
London 20
Redmond 20
Changsha 19
Turin 19
Falkenstein 17
Johannesburg 17
Ottawa 17
Redondo Beach 17
Des Moines 16
Falls Church 16
Frankfurt am Main 16
Seoul 16
Zhengzhou 16
Bulle 15
Hải Dương 15
Jiaxing 15
Mahé 15
Toronto 15
Amsterdam 14
Jakarta 14
Rome 14
Shanghai 14
Atlanta 11
Bengaluru 11
Hangzhou 11
Quận Ba 11
Abeokuta 10
Amman 10
Biên Hòa 9
Montreal 9
Moscow 9
Quận Bình Thạnh 9
Shijiazhuang 9
Taizhou 9
Verona 9
Warsaw 9
Yubileyny 9
Can Tho 8
Casalecchio di Reno 8
Kuban 8
Paris 8
San Francisco 8
Stockholm 8
Totale 7.727
Salva come PNG Salva come JPEG
Nome #
Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER-2. 386
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft 343
Different mtDNA mutations modify tumor progression in dependence of the degree of respiratory complex I impairment 272
A multi-DNA preventive vaccine for p53/Neu driven cancer syndrome 268
Respiratory complex I is essential to induce a Warburg profile in mitochondria-defective tumor cells 263
Preclinical therapy of disseminated HER-2+ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus. 253
Cancer Vaccines Co-Targeting HER2/Neu and IGF1R 248
Rethinking herpes simplex virus: the way to oncolytic agents. 238
Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2−/−;Il2rg−/− Mice and Treatment with PI3K Inhibitor 230
Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression 221
Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. 219
Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy 216
Apc10.1: an ApcMin/+ intestinal cell line with retention of heterozygosity. 211
Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model 209
Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. 203
Endothelin-3 production by human rhabdomyosarcoma: A possible new marker with a paracrine role. 203
A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins 200
In silico modeling and in vivo efficacy of cancer preventive vaccinations 200
HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines 199
A Mutation Threshold Distinguishes the Antitumorigenic Effects of the Mitochondrial Gene MTND1, an Oncojanus Function 194
Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis 189
Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma. 188
Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice. 188
High metastatic efficiency of human sarcoma cells in Rag2/gamma c double knockout mice provides a powerful test system for antimetastatic targeted therapy 188
Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis 187
Antimetastatic activity of a preventive cancer vaccine. 187
Human responses against HER-2-positive cancer cells in human immune system-engrafted mice. 186
Oncolytic herpes virus retargeted to HER-2. 181
HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response 181
Herpesviruses as oncolytic agents 179
Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4. 179
Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells 178
OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis 177
Alterations in folate-dependent one-carbon metabolism as colon cell transition from normal to cancerous 177
Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas 174
Immunoprevention and immunotherapy of mammary carcinoma 172
Immunological prevention of a multigene cancer syndrome 166
Inhibition of prostate carcinogenesis by combined active immunoprophylaxis. 162
Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesis. 162
Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario. 160
The molecular basis of herpesviruses as oncolytic agents. 160
New target antigens for cancer immunoprevention 155
HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy 155
Expression of different isoforms of the B-cell mutator activation-induced cytidine deaminase (AID) in BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL) Patients 152
Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells 150
Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent 149
2011: the immune hallmarks of cancer 148
Preclinical HER-2 Vaccines: From Rodent to Human HER-2 148
Preclinical vaccines against mammary carcinoma. 148
Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system 148
Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12 engineered allogeneic cell vaccine 147
APC10.1 cells as a model for assessing the efficacy of potential chemopreventive agents in the ApcMin mouse model in vivo. 146
Molecular and cellular biology of rhabdomyosarcoma 145
Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. 144
Gene expression profiling differences between synchronous and metachronous metastases of colorectal cancer. 142
A limited autoimmunity to p185neu elicited by DNA and allogeneic cell vaccine hampers the progression of preneoplastic lesions in HER-2/NEU transgenic mice. 142
Vaccines and other immunological approaches for cancer immunoprevention 137
Delivery of CD44shRNA/nanoparticles within cancer cells: perturbation of hyaluronan/CD44v6 interactions and reduction in adenoma growth in Apc Min/+ mice. 134
Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells 128
Cancer biology, what we know and what we don't know. 119
Methods of treating bone cancer 114
null 99
Immunotherapy 94
Cancer immunoprevention 84
Functional stability, progression and evolution of targeted drug sensitivity of HER-2-positive breast cancer patient-derived xenografts 69
Totale 11.694
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.493
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.493
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.384 144 40 105 57 124 85 42 101 52 97 310 227
2022/20231.656 203 237 91 226 105 111 43 81 203 72 136 148
2023/2024328 17 63 20 34 23 57 24 30 4 23 10 23
2024/20251.376 135 179 130 72 228 97 76 42 17 71 56 273
2025/20263.093 386 244 286 225 365 150 270 82 664 267 89 65
2026/202742 42 0 0 0 0 0 0 0 0 0 0 0
Totale 11.694